The FDA has cleared expanded access for daraxonrasib, a targeted therapy for first-line pancreatic cancer. The clearance follows Phase 3 trial results published in the New England Journal of Medicine showing median overall survival of 13.2 months for patients on daraxonrasib versus 6.7 months for the control arm — nearly double the survival in a cancer type that has resisted improvement for decades. [1]

Expanded access, sometimes called compassionate use, is a regulatory pathway that allows patients with serious or life-threatening conditions to receive investigational treatments before full approval. The FDA's "safe to proceed" determination does not mean daraxonrasib is approved; it means the agency has reviewed the safety profile and concluded that the risk-benefit calculation supports access for patients who have no approved alternatives and cannot enroll in a trial.

Pancreatic cancer has one of the lowest five-year survival rates of any major malignancy. First-line treatment outcomes have not substantially improved in years. A Phase 3 result showing 13.2 versus 6.7 months median overall survival — a nearly two-month absolute gain in a disease where gains are measured in weeks — represents a clinically meaningful finding by any standard in this space. [1] The expanded access pathway now allows patients outside trial settings to receive the drug while the full approval process proceeds. The gap between expanded access and approval can be months or longer. For patients with pancreatic cancer diagnosed today, that interval is not abstract.

-- KENJI NAKAMURA, Tokyo